Form D · Biotechnology
Sycamore Biopharma, Inc.
West Columbia, SC · CIK 0001797706
Offering snapshot reported Mar 5, 2021 · SEC filing
- Reported sold
- Yet to sell Offering amount: $175K
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 5, 2021 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Dec 20, 2019 | Initial | $500,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-391337
Source: Form D, filed Mar 5, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark T. Hamann | Director, Executive |
| William Lamar | Director, Executive |
| H. Lee Mashburn, Jr. | Director, Executive |
| Chris Sadek | Director |
| R. Tyler Stone Iii | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
167 Lott Ct.
West Columbia, SC, 29169
West Columbia, SC, 29169